SCHEMBL4773434

SCHEMBL4773434

CCOc1ccc2nc(SC3CCN(C(=O)O)CC3)sc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.57
RAB9A P51151 5/20 0.56
NPC1 O15118 3/20 0.56
ALDH1A1 P00352 8/20 0.55
MAPT P10636 8/20 0.55
HTT P42858 5/20 0.55
LMNA P02545 4/20 0.55
KDM4E B2RXH2 1/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
KMT2A Q03164 4/20 0.55
HPGD P15428 3/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 2/20 0.52
POLB P06746 1/20 0.50
ALOX5 P09917 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2774177 0.80 PPARA (0.55) PPARARAB9ANPC1ALDH1A1MAPT
Hydrochloric Acid SCHEMBL4775384 0.80 RAB9A (0.53) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL3609842 0.74 MAPT (0.77) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL4768526 0.74 PPARA (0.51) PPARAALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL1808012 0.74 DDB1 (0.49) RAB9ANPC1ALDH1A1MAPTHTT
SCHEMBL6689290 0.73 PDK1 (0.69) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL6902202 0.73 MAPT (0.66) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL14675979 0.73 MAPT (0.67) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL11707397 0.72 RAB9A (0.52) PPARARAB9ANPC1ALDH1A1MAPT
SCHEMBL6665955 0.72 MAPT (0.64) PPARARAB9ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 PPARA 4115/4885RAB9A 2291/4885NPC1 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.